Balance therapeutic efficacy and cardiac safety assessment early in drug discovery using in vitro modelling and human-relevant New Approach Methodologies (NAMs) to improve prediction of clinical outcomes and reduce late-stage failure.
Small molecule
cardiac therapeutics
Navigate the critical balance between efficacy and cardiac safety by identifying beneficial and adverse effects early in development with in vitro cardiac models.
Clyde supports lead optimisation programs using human iPSC-derived cardiomyocytes and adult cardiomyocytes to evaluate compound effects on cardiac function and performance. Our integrated multi-parameter platform is at the base of our drug-induced cardiotoxicity testing and generates comprehensive functional data—including electrophysiology, calcium dynamics, and contractility—to guide medicinal chemistry decisions and optimise compound design.
Gene therapy
for cardiac diseases
Develop tailored cardiomyocyte assays to evaluate gene therapy approaches, supporting efficacy assessment in human-relevant hiPSC-derived cardiomyocyte disease models and chronic exposure protocols. to replicate cardiac disease phenotypes and assess therapeutic response.
Our experience working with regulatory agencies and industry partners supports development of assays aligned with evolving regulatory expectations.
Aligned with New Approach Methodologies (NAMs) and Regulatory Guidance
Regulatory guidance such as the one by the FDA is shifting drug discovery toward human-relevant NAMs that integrate in vitro cardiomyocyte models with computational approaches to improve prediction of clinical outcomes.
Clyde’s platform of human-relevant cardiac models supports this transition through:
hiPSC-derived cardiomyocyte assays
integrated functional readouts (voltage, calcium, contractility)
CiPA-aligned and translational cardiac safety data
Obtain human-relevant functional cardiac data:
Our team of experts will leverage the exceptional functionality of the CellOPTIQ® platform to generate and analyze high-content functional data from both hiPSC-derived and adult cardiomyocytes to assess therapeutic effects on cardiac physiology and performance.
Representative data: Cardiac Response to Therapeutic Compounds
Functional data reveals compound-specific effects on contractility and cardiac performance, supporting efficacy and safety evaluation from our translational cardiac model.
Applications across drug discovery
Target Validation
Validate cardiac targets using human-relevant cardiomyocyte models.
Compound Optimisation
Optimize compounds by balancing efficacy with cardiac safety profiles.
Biomarker Identification & Validation
Identify functional biomarkers of cardiac response and therapeutic activity.
Preclinical Cardiac Safety Assessment
Evaluate potential cardiac liabilities alongside therapeutic effects.
Accelerate Your Cardiac Drug Discovery Program
Work with our scientists to evaluate efficacy and cardiac safety using human-relevant cardiomyocyte models.
Speak to an expert Or contact us at info@clydebio.com